PT - JOURNAL ARTICLE AU - Xiaoyu Che AU - Christopher R. Brydges AU - Yuanzhi Yu AU - Adam Price AU - Shreyas Joshi AU - Ayan Roy AU - Bohyun Lee AU - Dinesh K. Barupal AU - Aaron Cheng AU - Dana March Palmer AU - Susan Levine AU - Daniel L. Peterson AU - Suzanne D. Vernon AU - Lucinda Bateman AU - Mady Hornig AU - Jose G. Montoya AU - Anthony L. Komaroff AU - Oliver Fiehn AU - W. Ian Lipkin TI - Evidence for Peroxisomal Dysfunction and Dysregulation of the CDP-Choline Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome AID - 10.1101/2021.06.14.21258895 DP - 2022 Jan 01 TA - medRxiv PG - 2021.06.14.21258895 4099 - http://medrxiv.org/content/early/2022/01/11/2021.06.14.21258895.short 4100 - http://medrxiv.org/content/early/2022/01/11/2021.06.14.21258895.full AB - Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic and debilitating disease that is characterized by unexplained physical fatigue unrelieved by rest. Symptoms also include cognitive and sensory dysfunction, sleeping disturbances, orthostatic intolerance, and gastrointestinal problems. A syndrome clinically similar to ME/CFS has been reported following well-documented infections with the coronaviruses SARS-CoV and MERS-CoV. At least 10% of COVID-19 survivors develop post acute sequelae of SARS-CoV-2 infection (PASC). Although many individuals with PASC have evidence of structural organ damage, a subset have symptoms consistent with ME/CFS including fatigue, post exertional malaise, cognitive dysfunction, gastrointestinal disturbances, and postural orthostatic intolerance. These common features in ME/CFS and PASC suggest that insights into the pathogenesis of either may enrich our understanding of both syndromes, and could expedite the development of strategies for identifying those at risk and interventions that prevent or mitigate disease.Methods Using regression, Bayesian and enrichment analyses, we conducted targeted and untargeted metabolomic analysis of 888 metabolic analytes in plasma samples of 106 ME/CFS cases and 91 frequency-matched healthy controls.Results In ME/CFS cases, regression, Bayesian and enrichment analyses revealed evidence of peroxisomal dysfunction with decreased levels of plasmalogens. Other findings included decreased levels of several membrane lipids, including phosphatidylcholines and sphingomyelins, that may indicate dysregulation of the cytidine-5’-diphosphocholine pathway. Enrichment analyses revealed decreased levels of choline, ceramides and carnitines, and increased levels of long chain triglycerides (TG) and hydroxy-eicosapentaenoic acid. Elevated levels of dicarboxylic acids were consistent with abnormalities in the tricarboxylic acid cycle. Using machine learning algorithms with selected metabolites as predictors, we were able to differentiate female ME/CFS cases from female controls (highest AUC=0.794) and ME/CFS cases without self-reported irritable bowel syndrome (sr-IBS) from controls without sr-IBS (highest AUC=0.873).Conclusion Our findings are consistent with earlier ME/CFS work indicating compromised energy metabolism and redox imbalance, and highlight new abnormalities that may provide insights into the pathogenesis of ME/CFS.One Sentence Summary Plasma levels of plasmalogens are decreased in patients with myalgic encephalomyelitis/chronic fatigue syndrome suggesting peroxisome dysfunction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Institutes of Health U54 AI138370 (Center for Solutions for ME/CFS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Columbia University Irving Medical Center (CUIMC) Institutional Review Board. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.α -KGα-ketoglutarateβ2AdRβ2 Adrenergic receptorACacetylcholineAdaLassoadaptive LassoAUROCArea under the Receiver Operating Characteristic curveBAbiogenic aminesBFBayes factorsBICBayesian information criterionBMABayesian Model AverageBMIbody mass indexCDP-cholinecytidine-5’-diphosphocholineCIconfidence intervalCLcomplex lipidsCSH-QTOF MSquadrupole time-of-flight mass spectrometryCVcoefficients of variationDAGdiacylglycerolDHAdocosahexanoic acidDSQDePaul Symptom QuestionnaireEpODEePoxy fatty acidsFDRfalse discovery rateGC-ToF MSgas chromatography/time-of-flight mass spectrometryGIgastrointestinalGPCRG protein coupled receptorsHDIhighest density credible intervalHEPEhydroxy-eicosapentaenoic acidHILIC-QTOF-MShydrophilic interaction liquid chromatography/quadrupole time-of-flight mass spectrometryLassoleast absolute shrinkage and selection operatorLCliquid chromatographyLPClysophophatidycholinesM3AChRM3 Acetylcholine receptorME/CFSmyalgic encephalomyelitis/chronic fatigue syndromeMFIMultidimensional Fatigue InventoryMSmass spectrometry-based assaysOLoxylipinsPASCpost acute sequelae of SARS-CoV-2 infectionPCAprincipal component analysisPCphosphatidycholinesPEphosphatidylethanolaminesPGD2prostaglandin D2PGF2αprostaglandin F2 αPMprimary metabolitesPSQIPittsburgh Sleep Quality IndexRFRandom ForestsROCReceiving Operating CharacteristicROSreactive oxygen speciesSAMsorting and assembly machinerySDstandard deviationSF-36Short Form 36 Health SurveySMsphingomyelinsr-IBSself-reported irritable bowel syndromeTCAtricarboxylic acidTGtriglyceridesTMAOtrimethylamine N-oxide